Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × NSCLC × aflutinib × Clear all

Phase

Phase 2 3 Phase 1 3 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Non Small Cell Lung Cancer NSCLC 1 Neoplasm, Residual 1 NSCLC 1 Advanced Lung Cancer 1 Adenocarcinoma of Lung 1

Interventions

sulindac sulfone 1 nimotuzumab 1 aflutinib 1 Pemetrexed 1 Clinical Trials, Phase I as Topic 1 Carboplatin 1 BID protein, human 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05994131 2025-04-30

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡